LRP1 Regulates Architecture of the Vascular Wall by Controlling PDGFRβ-Dependent Phosphatidylinositol 3-Kinase Activation

被引:56
|
作者
Zhou, Li
Takayama, Yoshiharu
Boucher, Philippe
Tallquist, Michelle D.
Herz, Joachim
机构
[1] Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, TX
[2] Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX
[3] Department of Pharmacology, University of Strasbourg, Strasbourg
来源
PLOS ONE | 2009年 / 4卷 / 09期
关键词
RECEPTOR-RELATED PROTEIN; PHOSPHOLIPASE-C-GAMMA; PHOSPHOINOSITIDE; 3-KINASE; MARFAN-SYNDROME; TGF-BETA; GROWTH-INHIBITION; MOUSE MODEL; PATHOGENESIS; CELLS; INVOLVEMENT;
D O I
10.1371/journal.pone.0006922
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Low density lipoprotein receptor-related protein 1 (LRP1) protects against atherosclerosis by regulating the activation of platelet-derived growth factor receptor beta (PDGFR beta) in vascular smooth muscle cells (SMCs). Activated PDGFR beta undergoes tyrosine phosphorylation and subsequently interacts with various signaling molecules, including phosphatidylinositol 3-kinase (PI3K), which binds to the phosphorylated tyrosine 739/750 residues in mice, and thus regulates actin polymerization and cell movement. Methods and Principal Findings: In this study, we found disorganized actin in the form of membrane ruffling and enhanced cell migration in LRP1-deficient (LRP1-/-) SMCs. Marfan syndrome-like phenotypes such as tortuous aortas, disrupted elastic layers and abnormally activated transforming growth factor beta (TGF beta) signaling are present in smooth muscle-specific LRP1 knockout (smLRP1-/-) mice. To investigate the role of LRP1-regulated PI3K activation by PDGFR beta in atherogenesis, we generated a strain of smLRP1-/- mice in which tyrosine 739/750 of the PDGFR beta had been mutated to phenylalanines (PDGFR beta F2/F2). Spontaneous atherosclerosis was significantly reduced in the absence of hypercholesterolemia in these mice compared to smLRP1-/- animals that express wild type PDGFR. Normal actin organization was restored and spontaneous SMC migration as well as PDGF-BB-induced chemotaxis was dramatically reduced, despite continued overactivation of TGF beta signaling, as indicated by high levels of nuclear phospho-Smad2. Conclusions and Significance: Our data suggest that LRP1 regulates actin organization and cell migration by controlling PDGFR beta-dependent activation of PI3K. TGF beta activation alone is not sufficient for the expression of the Marfan-like vascular phenotype. Thus, regulation of PI3 Kinase by PDGFR beta is essential for maintaining vascular integrity, and for the prevention of atherosclerosis as well as Marfan syndrome.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338
    Chaudhary, A
    King, WG
    Mattaliano, MD
    Frost, JA
    Diaz, B
    Morrison, DK
    Cobb, MH
    Marshall, MS
    Brugge, JS
    CURRENT BIOLOGY, 2000, 10 (09) : 551 - 554
  • [22] CD28-dependent killing by human YT cells requires phosphatidylinositol 3-kinase activation
    Lu, YL
    Rodriguez, R
    Bjorndahl, J
    Phillips, CA
    Trevillyan, JM
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (06) : 1278 - 1284
  • [23] 3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma
    Maurer, Matthew
    Su, Tao
    Saal, Lao H.
    Koujak, Susan
    Hopkins, Benjamin D.
    Barkley, Christina R.
    Wu, Jiaping
    Nandula, Subhadra
    Dutta, Bhaskar
    Xie, Yuli
    Chin, Y. Rebecca
    Kim, Da-In
    Ferris, Jennifer S.
    Gruvberger-Saal, Sofia K.
    Laakso, Mervi
    Wang, Xiaomei
    Memeo, Lorenzo
    Rojtman, Albert
    Matos, Tulio
    Yu, Jennifer S.
    Cordon-Cardo, Carlos
    Isola, Jorma
    Terry, Mary Beth
    Toker, Alex
    Mills, Gordon B.
    Zhao, Jean J.
    Murty, Vundavalli V. V. S.
    Hibshoosh, Hanina
    Parsons, Ramon
    CANCER RESEARCH, 2009, 69 (15) : 6299 - 6306
  • [24] Androgen Receptor-Dependent Activation of Endothelial Nitric Oxide Synthase in Vascular Endothelial Cells: Role of Phosphatidylinositol 3-Kinase/Akt Pathway
    Yu, Jing
    Akishita, Masahiro
    Eto, Masato
    Ogawa, Sumito
    Son, Bo-Kyung
    Kato, Shigeaki
    Ouchi, Yasuyoshi
    Okabe, Tetsuro
    ENDOCRINOLOGY, 2010, 151 (04) : 1822 - 1828
  • [25] Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression
    Nguyen, H
    Ramana, CV
    Bayes, J
    Stark, GR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) : 33361 - 33368
  • [26] Angiotensin II-induced delayed stimulation of phospholipase C γ1 requires activation of both phosphatidylinositol 3-kinase γ and tyrosine kinase in vascular myocytes
    Rakotoarisoa, Lala
    Carricaburu, Valrie
    Leblanc, Catherine
    Mironneau, Chantal
    Mironneau, Jean
    Macrez, Nathalie
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2006, 10 (03) : 734 - 748
  • [27] 1α,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase
    Rebsamen, MC
    Sun, JX
    Norman, AW
    Liao, JK
    CIRCULATION RESEARCH, 2002, 91 (01) : 17 - 24
  • [28] Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt
    Chen, YC
    Su, YN
    Chou, PC
    Chiang, WC
    Chang, MC
    Wang, LS
    Teng, SC
    Wu, KJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (37) : 32505 - 32511
  • [29] Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway
    Akimoto, T
    Kusano, E
    Inaba, T
    Iimura, O
    Takahashi, H
    Ikeda, H
    Ito, C
    Ando, Y
    Ozawa, K
    Asano, Y
    KIDNEY INTERNATIONAL, 2000, 58 (01) : 269 - 282
  • [30] Retinoic acid inhibits transformation by preventing phosphatidylinositol 3-kinase dependent activation of the c-fos promoter
    Yachi Chen
    Robert Freund
    Mark Listerud
    Zuohong Wang
    David A Talmage
    Oncogene, 1999, 18 : 139 - 148